- Investopedia•58 minutes ago
These Nasdaq-100 components show stronger buying interest than price gains, predicting the price will play catch up in coming months.
- Benzinga•4 hours ago
Amgen, Inc. (NASDAQ: AMGN ) announced that the Phase 3 CLARION trial for Kyprolis in first-line multiple myeloma (MM) did not meet the primary endpoint. Goldman Sachs’ Terence Flynn maintains a Buy rating ...
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||169.38 x 100|
|Ask||169.41 x 100|
|Day's Range||169.25 - 172.22|
|52wk Range||135.64 - 176.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.38|
|Avg Vol (3m)||2,857,300|
|Dividend & Yield||4.00 (2.31%)|